A recent study demonstrated that the increase in inflammation is particularly observed in MPN patients with TP53 mutations, either heterozygous or multi-hit, where the mutant myeloid cells gain a selective advantage over erythroid cells, especially those with WT TP53, which leads to a distortion in the ratio between erythroid and myeloid progenitor cells [68]. This evidence concerns the gene TP53 and myeloproliferative disorder.